The Association for Clinical Oncology (ASCO) is outlining key priorities for the next generation of biomedical innovation policy in response to “A Roadmap for 21st Century Cures,” a white paper ...

The Association for Clinical Oncology (ASCO) is urging lawmakers to prioritize federal cancer research in Fiscal Year (FY) 2026 by providing the National Institutes of Health (NIH), National Cancer ...

On May 29, the American Society of Clinical Oncology (ASCO) issued a new position statement with recommendations to properly implement and regulate artificial intelligence (AI) in the prior ...

“This trial emphasizes the importance of germline and somatic testing in patients with metastatic prostate cancer at the time of diagnosis; homologous recombination repair mutations have been ...

The Minnesota Society of Clinical Oncology (MSCO) is the recipient of the 2024 Jeffery C. Ward Affiliate Advocacy Award. The Association for Clinical Oncology presented the award during the State ...

“The findings from Destiny-Breast09 represent a new first line standard treatment option for HER-2 positive metastatic breast cancer. The duration of therapy can now be measured in years and gives us ...

Main Takeaway Perioperative treatment with durvalumab (Imfinzi) and chemotherapy led to longer survival without cancer recurrence, progression or treatment-related complications for patients with ...

“This early but promising observational study suggests a powerful synergy: patients with stage III colon cancer who embraced anti-inflammatory foods and exercised regularly showed the best overall ...

“This is the first randomized phase 3 trial in patients with stage III and high-risk stage II colon cancer to demonstrate that post-treatment exercise is both achievable and effective in improving ...

“The early switch approach of the SERENA-6 clinical trial resulted in a 56% reduction in the risk of disease progression or death for patients who switched to treatment with camizestrant, allowing ...

“This study will change the standard of care for the subset of patients with deficient DNA mismatch repair colon cancer by incorporating atezolizumab to standard of care FOLFOX chemotherapy in the ...

“Adjuvant nivolumab with chemoradiotherapy in resected high-risk head and neck squamous cell carcinoma improved disease-free survival regardless of tumor PD-L1 status. This is the first study to show ...